Cash position as of
As of
With the implementation of additional cost-cutting measures, PHAXIAM Therapeutics estimates that its current cash position will enable the Company to finance its current programs and expected operating expenses until the end of
At the same time, PHAXIAM is continuing discussions aimed at refinancing the company during the first half of 2024, to pursue its project.
Financial calendar for 20241
- Update on business and key financial data for 4th quarter 2023: press release on
March 20, 2024 (after US market close), followed by a conference call and webcast onMarch 21, 2024 (2:30 pm CET /8:30 am ET ). - Update on business and key financial data for Q1 2024: press release on
May 15, 2024 (after US market close), followed by a conference call and webcast onMay 16, 2024 (2:30 pm CET /8:30 am ET ). - Annual General Meeting on
June 28, 2024 - Update on business and key financial data for Q2 2024: press release on
September 25, 2024 (after US market close), followed by a conference call and webcast onSeptember 26, 2024 (2:30 pm CET /8:30 am ET ). - Update on business and key financial data for Q3 2024: press release on
November 13, 2024 (after US market close), followed by a conference call and webcast onNovember 14, 2024 (2:30 pm CET /8:30 am ET ).
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in
For more information, please visit www.phaxiam.com
Contacts
PHAXIAM COO & CFO +33 4 78 74 44 38 investors@phaxiam.com | NewCap Investor Relations Arthur Rouillé Media Relations +33 1 44 71 94 94 phaxiam@newcap.eu |
Forward-looking information
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical programs , development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond PHAXIAM's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the inability to maintain the listing of PHAXIAM’s shares on the Nasdaq Capital Market and the Euronext regulated market; (2) changes in applicable laws or regulations; (3) the possibility that PHAXIAM may be adversely affected by other economic, business and/or competitive factors; and (4) other risks and uncertainties indicated from time to time in PHAXIAM’s regulatory filings. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s
1 Information subject to modification
Attachment
- PR_PHAXIAM_18012024_Agenda_EN_VF2
Source:
2024 GlobeNewswire, Inc., source